After Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and Middle East Respiratory Syndrome Coronavirus (MERS-CoV), Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is the third coronavirus posing serious threats to human society in this century and is the causative agent of COVID-19 disease. With 67,367,046 confirmed cases and 1,545,331 deaths worldwide, this disease has become a global emergency. Mortality rates are higher among the elderly population with comorbidities such as cancer, diabetes, cardiovascular problems, and hypertension obesity. Increased oxidative stress/cytokine storm also is one of the main causes of COVID-19 associated complications. Carnosine is a well-established anti-inflammatory, anti-aging, antihypertensive, antineoplastic, antichelating, and neuroprotective agent which is helpful in maintaining the body’s pH balance. It is a naturally occurring dipeptide and is present in human skeletal muscles, cardiac muscles and brain. The compound reduces the concentration of oxygen-free-radicals, chelates heavy metals such as iron, zinc and copper, as well as inhibiting protein glycation and the generation of protein carbonyls. The Carnosine/non-hydrolysed isopeptide of Carnosine/N-acetylcarnosine, which is available without prescription, merits further consideration as a low-cost prophylaxis approach to COVID-19 and the associated complication of this disease. This is especially relevant to low-resource regions of the world which may be the last to achieve population-based herd immunity through vaccination.
The Prophylaxis Potential of Carnosine in the Management of COVID-19
Published: 11 January 2021 by MDPI in The 3rd International Electronic Conference on Environmental Research and Public Health —Public Health Issues in the Context of the COVID-19 Pandemic session Public Health Statistics and Risk Assessment
Keywords: Carnosine; COVID-19; anti-inflammatory; anti-aging; antihypertensive; antineoplastic; antichelating; neuroprotective